Xenon Pharmaceuticals Inc. (XENE) — Insider Activity & Signal

Healthcare · Biotechnology · Market cap $3.5B · $36.57 · 52-week range $35.75–$72.66

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

Date	Insider	Role	Shares	Price	Value	Source
2026-09-30	Kelly Thomas Patrick	officer: Chief Financial Officer	15,000	$37.32	$559,740	SEC Form 4
2026-09-30	MORTIMER IAN	director, officer: PRESIDENT & CEO	30,000	$37.38	$1,121,400	SEC Form 4

Financial health

Altman Z-Score 38.94 · Piotroski F-Score 2/9 · Cash $549M · Debt $8M

ClearOcean signal read

ClearOcean's model currently scores XENE as a validated signal (8+/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Primary filings: SEC EDGAR — XENE Form 4
How ClearOcean reads insider activity

Last updated October 07, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.